Trial Profile
A PHASE II STUDY OF MK-2206 IN PATIENTS WITH PROGRESSIVE, RECURRENT/METASTATIC ADENOID CYSTIC CARCINOMA
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- 10 Nov 2023 Results published in the Cancer
- 02 Jun 2015 Results in 16 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has not been met. (Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1)